Short answer
Cogent Biosciences, Inc. (COGT) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release reports Cogent Biosciences’ financial results for quarter ended September 30, 2026.
Cogent Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release reports Cogent Biosciences’ financial results for quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed earnings release and financial figures for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 net loss $111.4M, widening from $80.9M as operating expenses rose to $117.2M
- Cash, equivalents and marketable securities $791.1M, expected to fund operations into late 2028
- Three PDUFA dates create near-term catalysts: GIST November 30, 2026, NonAdvSM December 30, 2026, AdvSM June 29, 2027
- FDA accepted the AdvSM NDA, advancing bezuclastinib toward potential approval in a third indication
- G&A expense $42.1M, up from $14.4M, reflecting commercial infrastructure and launch preparation for bezuclastinib
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cogent Biosciences, Inc. 8-K filings
Get the next COGT 8-K as it lands
Follow COGT for push alerts, or ask the research agent what this filing means.